Autolus Therapeutics plc ADR (NASDAQ: AUTL) kicked off on Tuesday, up 12.10% from the previous trading day, before settling in for the closing price of $1.24. Over the past 52 weeks, AUTL has traded in a range of $1.11-$3.45.
During the last 5-year period, the sales growth of Healthcare Sector giant was 21.35%. While this was happening, its average annual earnings per share was recorded -12.14%. With a float of $240.34 million, this company’s outstanding shares have now reached $266.14 million.
Autolus Therapeutics plc ADR (AUTL) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Autolus Therapeutics plc ADR is 9.70%, while institutional ownership is 50.86%.
Autolus Therapeutics plc ADR (AUTL) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.09 earnings per share (EPS), higher than consensus estimate (set at -0.24) by 0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.56% during the next five years compared to 21.35% growth over the previous five years of trading.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Take a look at Autolus Therapeutics plc ADR’s (AUTL) current performance indicators. Last quarter, stock had a quick ratio of 5.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Looking closely at Autolus Therapeutics plc ADR (NASDAQ: AUTL), its last 5-days average volume was 7.78 million, which is a jump from its year-to-date volume of 2.49 million. As of the previous 9 days, the stock’s Stochastic %D was 31.63%.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 12.67%, which indicates a significant decrease from 59.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1010 in the past 14 days, which was lower than the 0.1178 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4886, while its 200-day Moving Average is $1.7514. However, in the short run, Autolus Therapeutics plc ADR’s stock first resistance to watch stands at $1.4833. Second resistance stands at $1.5767. The third major resistance level sits at $1.6633. If the price goes on to break the first support level at $1.3033, it is likely to go to the next support level at $1.2167. Now, if the price goes above the second support level, the third support stands at $1.1233.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
The company with the Market Capitalisation of 369.93 million has total of 266,141K Shares Outstanding. Its annual sales at the moment are 10,120 K in contrast with the sum of -220,660 K annual income. Company’s last quarter sales were recorded 21,190 K and last quarter income was -79,120 K.
